PRESCRIBING INFORMATION
|
IMPORTANT SAFETY INFORMATION
|
PATIENT WEBSITE
ACNE FRANCHISE
onexton
®
(clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/3.75%
retin-A micro
®
(tretinoin) Gel microsphere 0.06%, 0.08%
solodyn
®
(minocycline HCI, USP) extended release tablets
INSTANT
SAVING OFFER*
Toggle navigation
INSTANT
SAVINGS OFFER
*
ACNE FRANCHISE
onexton
®
(clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/3.75%
retin-A micro
®
(tretinoin) Gel microsphere 0.06%, 0.08%
solodyn
®
(minocycline HCI, USP) extended release tablets
Efficacy
Tolerability
See Results
Why Onexton
Patient Support
DESIGNED FOR
CUTANEOUS TOLERABILITY
NO PATIENTS DISCONTINUED TREATMENT IN CLINICAL TRIALS DUE TO AN ADVERSE EVENT
1
In a phase 3 clinical trial, mean cutaneous safety
and tolerability scores (range 0-3) were generally mild at 12 weeks
2,3
Severe
3
Moderate
2
Mild
1
Cutaneous Safety Evaluations
Tolerability Evaluations (Patient Reported)
Onexton
Vehicle
At Week 12, no more than 2% of patients studied showed moderate local skin reactions, and fewer than 1% showed severe reactions
2
Some skin reactions increased during treatment, peaked around Week 4, and returned to baseline or improved by Week 12
2
MOST COMMON ADVERSE EVENTS (AEs) OCCURRED IN <0.5% OF PATIENTS OVER 12 WEEKS
2
Contact dermatitis (0.4%)
|
Pruritus (0.4%)
|
Burning sensation (0.4%)
|
Rash (0.4%)
SEE VISIBLE RESULTS >